© Reuters.
In an impressive turn of events for SoFi Technologies (NASDAQ:), the financial services firm has not only seen its shares jump by 60% this year but also remains a compelling investment, according to recent reports. The company has exhibited a remarkable year-over-year revenue growth of 142% and is on track to achieve GAAP profitability in the fourth quarter of 2023, with expectations to maintain profitability throughout 2024.
The growth trajectory of SoFi can be attributed to its successful transformation into a full-fledged banking service provider since its inception in 2022. A significant contributor to this success is the financial services segment, which generated over $118 million in revenue in the latest quarter. Additionally, SoFi’s banking division has been prolific in attracting deposits, adding $2.9 billion in Q3 alone, bringing the total deposit base close to $16 billion. Notably, 90% of these deposits are direct and carry an average interest rate of 4.12%. This strategic approach to deposits has provided SoFi with a cost advantage for its lending operations, as it is significantly lower than the warehouse facility rate of 6.31%. Consequently, SoFi’s net interest margin has improved from 4.4% in Q1 of 2021 to 6% at present. The company’s membership also reflects its growing market presence, now standing at 6.9 million.
TransMedics (NASDAQ:TMDX) shares have also experienced a notable increase in value by 50%, with the company still being recognized as a viable investment opportunity. This optimism is backed by TransMedics’ recent revenue surge of 159%. The company’s innovative Organ Care System (OCS) has been pivotal, extending the viability timeline for donated organs up to thirty hours and achieving an impressive lung utilization rate of 87%.
TransMedics’ strategic move to integrate its Summit Aviation acquisition and fleet of planes has paid off handsomely, contributing to the significant sales growth witnessed in the recent quarter. With plans to establish a coast-to-coast logistical network, TransMedics aims to boost organ utilization rates further and streamline the organ transport process. After accounting for one-time acquisition costs, the company reported a healthy net profit margin of 6% in Q3 and has set an ambitious goal to expand from facilitating 2,000 transplants on its National OCS Program (NOP) in 2023 to 10,000 by 2028.
Despite the substantial rise in SoFi’s stock price this year, it remains attractively priced with a price-to-sales ratio of just 3.5, which is considerably lower than its historical average as a publicly traded entity. This suggests that both SoFi Technologies and TransMedics are not only experiencing strong growth but also continue to offer promising investment opportunities for those looking at their current performance and future potential.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
